How has ORMP's EPS trended since 2022?

Oramed Pharmaceuticals (ORMP) has experienced a volatile EPS trend over the past two years, with a significant decline in the most recent quarter ending on December 31, 2024. Here's a detailed analysis: 1. **Significant Decline in the Latest Quarter**: The EPS for Q4 2024 was -$0.48, which is a substantial decrease from the previous quarter's EPS of $0.14. This indicates a sharp deterioration in the company's profitability during this period. 2. **Comparison with the Baseline Quarter**: When compared to the baseline quarter ending on December 31, 2022, the EPS has decreased by -2.78%. This suggests that the company's financial performance has not only declined but also worsened relative to the initial period. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |ORMP|ORMP.O|Oramed|2022 Q1|-17.39130434782609|-0.27|186| |ORMP|ORMP.O|Oramed|2022 Q2|-125.00000000000003|-0.27|186| |ORMP|ORMP.O|Oramed|2022 Q3|14.285714285714285|-0.18|186| |ORMP|ORMP.O|Oramed|2023 Q1|70.37037037037037|-0.08|186| |ORMP|ORMP.O|Oramed|2023 Q2|88.8888888888889|-0.03|186| |ORMP|ORMP.O|Oramed|2023 Q3|55.55555555555556|-0.08|186| |ORMP|ORMP.O|Oramed|2024 Q1|150|0.04|186| |ORMP|ORMP.O|Oramed|2024 Q2|833.3333333333334|0.22|186| |ORMP|ORMP.O|Oramed|2024 Q3|-499.9999999999999|-0.48|186| In summary, Oramed Pharmaceuticals has seen a stark decline in its EPS, which is a concerning indicator of the company's financial health and operational performance. The substantial decrease in EPS from the previous quarter to the latest quarter highlights the need for urgent strategic interventions to stabilize and improve the company's financial outlook.